News

Oxford Cancer Biomarkers welcomes major investment partnership with MGMED, Inc.

Investment will drive rapid uptake of OCB’s cancer tests and expand its development pipeline

Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced that it has received significant investment from MGMED, Inc. based in, Geumchun-gu, Seoul, Korea.

The investment will allow OCB to increase market penetration for its existing suite of precision oncology tests, in addition to expediting the development and launch of novel diagnostic technologies. OCB currently offers it’s ColoTox and ColoProg diagnostic tests to patients in the United Kingdom. The new investment will allow OCB to further its core aim of making precision oncology diagnostics a daily reality for millions of cancer sufferers around the world.

OCB has developed a suite of diagnostic tests, initially for colorectal cancer (CRC), to personalise current treatment pathways and plans to develop similar tests for other cancer indications. CRC is the third most commonly diagnosed malignancy and the fourth leading cause of cancer related deaths in the world. As of 2012, 1.4 million new cases of colorectal cancer were diagnosed year, and over half of these cases prove fatal.

MGMED, Inc, is a leading molecular diagnostics organisation, focussed on bringing cutting edge molecular diagnostic technologies to market. The team at MGMED has extensive experience in product development and launch including clinical development, regulatory strategy, clinical laboratory services, sales and marketing. MGMED’s core business model is driven by patient and clinician needs.

Lee Byong Hwa, CEO of MGMED, commented “We are delighted to become a shareholder in one of the pioneers in biomarker technologies. Through this partnership, we look forward to supporting the continued growth and development of the Company.”

Prof David Kerr, Chief Medical Officer of OCB, commented “This partnership signifies the beginning of a long and productive relationship between our two companies. We believe that several strong areas of synergy between MGMED and OCB will allow patients and clinicians worldwide to reap the benefits of our endeavours”

About Oxford Cancer Biomarkers

Oxford Cancer Biomarkers translates ground-breaking cancer research into predictive diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Medical Sciences Division in Oxford University. The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University. Investors in OCB include Longwall Venture Partners LLP, Esperante BV and the University.

For more information, please visit: http://www.oxfordcancerbiomarkers.com

Contact details
Oxford Cancer Biomarkers Ltd
Tel: +44 1865 784743
David Oxlade, Chairman

About MGMED, Inc.

MGMED is a genetic testing service provider in Korea, based on the DNA chip technology. The company has Korean BAC library and manufacture microarrays-Array Comparative Genomic Hybridization (CGH). MGMED’s genetic testing service is aimed at detecting genetic abnormalities from DNA extracted from cord blood, blood samples from newborns and others, stem cells and cancer cells. The company was founded by Macrogen Inc. which is a global company specialized in the field of human genome information and bioinformatics and located in Korea.

Contact details
10F, Elysia bldg. 173, Digital-ro, Geumchun-gu, Seoul, Korea.
E-Mail:katechoi@MGMED.com
Tel : +82-2-890-8726
Lee Byong Hwa, CEO of MGMED

Oxford Cancer Biomarkers announces strategic collaboration with My-BioMed Biotechnology Co. Ltd

Collaboration will allow OCB’s suite of precision oncology In Vitro Diagnostic tests to be rolled out across the People’s Republic of China

Oxford, UK, April 2017 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced a strategic collaboration with My-BioMed Biotechnology Co. Ltd. based in Ningbo, Zhejiang, China.

The partnership includes a licencing deal that will allow My-BioMed Biotechnology Ltd to access OCB’s ColoTox, ColoProg and ColoPredict technologies and to drive uptake across the People’s Republic of China via a purpose built biomedical laboratory in Ningbo Meishan FTZ.

OCB has developed a suite of diagnostic tests for colorectal cancer (CRC) to personalise current treatment pathways and plans to develop similar tests for other cancer indications. As of 2015, 274,000 new cases of colorectal cancer are diagnosed every year in the Peoples Republic of China, 190,400 of these cases prove fatal.

My-BioMed (MBM) is a leading precision medicine organisation, focussed on bringing global innovation to the Chinese market. The team at MBM has extensive experience in product development and launch including clinical development, regulatory strategy, clinical laboratory services, sales and marketing. MBM’s core business model is driven by patient and clinician needs.

Jackson Zhu, CEO of MBM, commented “We are very happy to launch the first three proprietary CRC diagnostic tests discovered at Oxford University and developed by OCB, aimed at specifically benefitting patients in China. Through this partnership MBM and OCB have solidified a long term commitment to China, with the aim of developing and launching a suite of unique diagnostic products.”

Prof David Kerr, Chief Medical Officer of OCB, commented “Our strategic partnership with MBM will allow patients across China to access OCB’s suite of precision oncology diagnostic technologies. We are looking forward to working closely with MBM to tailor our offerings to the specific needs of the Chinese market and building a robust product pipeline of diagnostics specifically aimed at the Chinese population. This is an important step in our mission to drive global access to technologies that allow patient stratification and individually tailored treatment pathways.”

About Oxford Cancer Biomarkers

Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Medical Sciences Division in Oxford University. The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University. Investors in OCB include Longwall Venture Partners LLP, Esperante BV and the University.

For more information, please visit: http://www.oxfordcancerbiomarkers.com

Contact details
Oxford Cancer Biomarkers Ltd
Tel: +44 1865 784743
Nick La Thangue, CEO / David Oxlade, Chairman

About Ningbo My-BioMed Biotechnology Co.,Ltd.

In pursuit of its vision of “Bridging World Innovation in Precision Medicine”, My-BioMed (MBM) is dedicated to providing personalized solutions to clinicians and patients, and to building an integrated commercialization platform for innovation.

Supported by Ningbo Meishan’s Healthcare industry development strategy, MBM, established in May 2016, has attracted a group of talented individuals with experience across a range of disciplines including; business development, market access, clinical development, registration, clinical lab services, sales and marketing. Located at Ningbo Meishan Free Trade Port, My-BioMed Clinical Laboratory, MBM wholly owned subsidiary, has been granted pre-approval from the Health and Family Plan Commission, and will be certified within this year.

Contact details
Ningbo My-BioMed Biotechnology Co., Ltd.
E-Mail:info@my-biomed.com

Jackson Zhu, CEO

Chemotherapy side effect predicting Oxford biotech firm secures CE marking

Oxford Cancer Biomarker’s ColoTox test will now be available to UK patients considering chemotherapy

Oxford, UK, 14th March 2017 – FOR IMMEDIATE RELEASE

Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow personalised medicine for cancer patients, has today announced the CE marking of ColoTox, its first in a series of in vitro diagnostic tests aimed at providing UK patients with access to precision oncology diagnostic technologies.

ColoTox is aimed at patients who are considering or about to undergo Capecitabine / 5FU based chemotherapy. The test examines genetic polymorphisms in the germline DNA of a patient identifying the presence of risk alleles; the patient’s physician is provided with a report describing a risk classification, allowing the patient’s oncologist to tailor therapy for that individual. Patient DNA is extracted from a standard venous blood sample and sent to OCB’s sequencing and analysis laboratories. The results of the analyses are then used to guide the individual patient treatment pathway.

OCB has developed a suite of diagnostic tests for colorectal cancer (CRC) to personalise current treatment pathways and plans to develop similar tests for other cancer indications. The test assesses the response that patients will undergo during cancer chemotherapy, and the likelihood that the patient will undergo life threatening toxicity. Colorectal cancer is the fourth most common cancer in the UK behind breast, lung and prostate cancer. Over 40,000 new cases are diagnosed in the UK every year and over 15,000 prove fatal.

Prof David Kerr, Chief Medical Officer of OCB, said:

“This is a very exciting time for OCB and the future of personalised cancer medicine. Our ColoTox test will align a widely used cancer chemotherapy treatment with the patients who are most likely to suffer serious, even life threatening side effects, permitting their oncologist to make an informed decision about the correct dose of chemotherapy, or in rare cases whether it should be given at all. There is an increasing national focus on chemotherapy safety and tests such as ColoTox will be of great importance as we seek to tailor cancer treatments to individual cancer patients.”

About Oxford Cancer Biomarkers

Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Medical Sciences Division in Oxford University. The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University. Investors in OCB’s include Longwall Venture Partners LLP, Esperante BV and the University.

For more information, please visit: http://www.oxfordcancerbiomarkers.com

Contact details

Oxford Cancer Biomarkers Ltd
Tel: +44 1865 784743
Nick La Thangue, CEO / David Oxlade, Chairman

Oxford Cancer Biomarkers announces ColoTox test for predicting cancer chemotherapy toxicity enters clinical studies

First patient enrolled in clinical utility study

Oxford, UK, 9th November 2016 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced that the first colorectal cancer patient was enrolled in the PRECISE trial featuring the ColoTox Assay.

The PRECISE trial; ‘Predicting, Recording and rEducing Chemotherapy Induced Side Effects’: a pilot feasibility study of a new germline genetic test for the risk of toxicity with fluoropyrimidine-based chemotherapy. The ColoTox assay improves the patient pathway in the treatment of colorectal cancer, by improving safety.

OCB has developed a suite of diagnostic tests for colorectal cancer (CRC) to personalise current treatment pathways and plans to develop similar tests for other cancer indications. The ColoTox test assesses the likelihood that the patient will suffer from life threatening toxicity, permitting the clinical team to make a priori dose reduction and lessen the chance of serious side effects and even chemotherapy induced death. Colorectal cancer is the fourth most common cancer in the UK behind breast, lung and prostate cancer. Over 40,000 new cases are diagnosed in the UK every year and over 15,000 prove fatal.

Prof David Kerr, Chief Medical Officer of OCB, commented “This is a very exciting time for OCB and the future of personalised cancer medicine. Our ColoTox test will align a widely used cancer chemotherapy treatment with the patients who are most likely to benefit, and reduce the chance of unwanted side-effects. It will be of great importance to colorectal cancer patients”.

OCB’s Investors include Longwall Venture Partners, Esperante and the University.

About Oxford Cancer Biomarkers

Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Medical Sciences Division in Oxford University. The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University. OCB’s investors include Longwall Venture Partners and Esperante.

For more information, please visit: http://www.oxfordcancerbiomarkers.com

About Longwall Venture Partners LLP

Longwall Venture Partners LLP manages £70m of Enterprise Capital Funds from which it invests in innovative, UK based, early stage companies in the healthcare, science and engineering sectors.

About Esperante

Esperante is a privately held life science venture investment company focussed on therapeutics and in vitro clinical diagnostics with a portfolio of 13 therapeutics and 3 diagnostics companies principally in the UK and USA

Contact details

Oxford Cancer Biomarkers Ltd
Tel: +44 1865 784743
Nick La Thangue, CEO / David Oxlade, Chairman

Oxford Cancer Biomarkers appoints Kathryn Kuhne as its Commercial and Marketing Director

Oxford, UK, 10 June 2016 Oxford Cancer Biomarkers has appointed Kathryn Kuhne as Commercial and Marketing Director, a key growth milestone for the company which aims to benefit cancer patients through developing molecular diagnostic tests that allow improved treatment decisions.

Oxford Cancer Biomarkers uses its molecular insights into disease and pathological processes to develop innovative diagnostic tests. “We are delighted to welcome Kathryn Kuhne to Oxford Cancer Biomarkers”, said Nick La Thangue, acting CEO. “Her past experience in driving profitable business growth through strong leadership with a strategic, innovative solution focussed approach will be particularly relevant as the Company expands to achieve substantial growth over the coming years through market launch and commercialisation of its proprietary diagnostic tests”.

Kathryn has 28 years’ experience within the pharmaceutical industry, 21 of which have been focussed within the oncology arena. She has been involved in the initial launches of 5 cancer drugs that changed the treatment pathways in colorectal, renal, prostate, liver, thyroid and breast cancers. During this time Kathryn has worked as a key account manager, key opinion development manager, market access manager, business development manager and national sales manager with companies Bayer, Sanofi-Aventis, Roche and Astellas.

Kathryn commented: “I am privileged to be joining Oxford Cancer Biomarkers at this exciting and important stage of its development. The company has huge potential – providing much needed diagnostic tests in the colorectal cancer arena. The tests align to the NHS 5 year forward view strategy, improving patient quality of life and securing cost effectiveness within the patient pathway for the NHS and private markets.

About Oxford Cancer Biomarkers

Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Medical Sciences Division in Oxford University. The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University.

For more information, please visit: http://www.oxfordcancerbiomarkers.com

Contact details

Oxford Cancer Biomarkers Ltd
Tel: +44 1865 784743
Nick La Thangue, CEO / David Oxlade, Chairman

Oxford Cancer Biomarkers announces Partnership with Room4

Oxford, UK, 18 January 2016 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced a partnership with Room4 a UK based imaging company to deliver new tests for cancer prognosis.

Room4 develops innovative high quality imaging software for pathology. OCB and Room4 have collaborated to develop new prognostic biomarkers for colorectal cancer to use in OCB’s ColoProg test.

Nicholas La Thangue, CSO of Oxford Cancer Biomarkers, commented: “We have had a collaboration with Room4 for some time which has been extremely productive and we are excited to take this collaboration to the next level with a formal partnership. The technology we have developed is a vast improvement on the current methods used to assess colorectal cancer prognosis and we expect these methods will be applicable to other cancer indications.”

About Oxford Cancer Biomarkers

Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Medical Sciences Division in Oxford University. The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University. For more information, please visit http://www.oxfordcancerbiomarkers.com or contact Nick La Thangue, CSO, on +44 1865 784743.

About Room4

For more information please visit: http://www.room4.eu

Oxford Cancer Biomarkers announces new investment to commercialise its colorectal cancer diagnostic tests

Oxford, UK, 14 December 2015 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced that it has secured new investment. Longwall Ventures co-invested with Esperante together with existing shareholders and a private investor.

OCB has developed a suite of diagnostic tests for colorectal cancer (CRC) to personalise current treatment pathways, and plans to develop similar tests for other cancer indications. The tests assess whether the patient will undergo a favourable response to CRC chemotherapy, and the likelihood that the disease will reoccur post-surgery.

Colorectal cancer is the fourth most common cancer in the UK behind breast, lung and prostate cancer. Over 40,000 new cases are diagnosed in the UK every year and over 15,000 prove fatal. This new investment will support the commercialisation of OCB’s two most advanced products ColoProg and ColoTox.

Prof David Kerr, Chief Medical Officer of OCB, commented “This is a very exciting time for OCB and the future of personalised cancer medicines. Our tests will align treatment with the most relevant disease, and be of great benefit to colorectal cancer patients.”

Prof Nick La Thangue, CEO/CSO, commented “The new investment will enable OCB to launch its two most advanced tests and become revenue-generating. This is a highly significant milestone that paves the way for OCB to leverage its scientific, medical and commercial insight to personalise treatment in other cancer indications.”

About Oxford Cancer Biomarkers

Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Medical Sciences Division in Oxford University. The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University.

For more information, please visit: http://www.oxfordcancerbiomarkers.com

About Longwall Venture Partners LLP

Longwall Venture Partners LLP manages £70m of Enterprise Capital Funds from which it invests in innovative, UK based, early stage companies in the healthcare, science and engineering sectors.

About Esperante

Esperante is a privately held life science venture investment company focussed on therapeutics and in vitro clinical diagnostics with a portfolio of 13 therapeutics and 3 diagnostics companies principally in the UK and USA.

Contact details

Oxford Cancer Biomarkers Ltd
Tel: +44 1865 784743
Nick La Thangue, CEO / David Oxlade, Chairman

Oxford Cancer Biomarkers announces UK patent filed

Oxford, UK, 07 Sep 2015 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced a UK patent has been filed for the use of a combination of biomarkers for improved cancer prognosis testing. This technology will be included in OCB’s ColoProg test which will allow surgeons and oncologists to better target adjuvant chemotherapy, to those individuals at highest risk of relapse and avoid chemotherapy in patients who have a high likelihood of cure by surgery alone.

David Kerr, CMO of Oxford Cancer Biomarkers, commented: “The protection of new IP is a key step in being able to strengthen OCB’s proprietary position for the ColoProg test. The ColoProg test has been developed to be seamlessly inserted into current clinical pathways for colorectal cancer and provides important information to treating oncologists. The protected IP should be translatable to other disease indications further strengthening OCBs commercial potential.”

About Oxford Cancer Biomarkers

Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Medical Sciences Division. The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University.

For more information, please visit www.oxfordcancerbiomarkers.com or contact Nick La Thangue, CSO, on +44 1865 784743

Oxford Cancer Biomarkers announces the EU patent for the use of the biomarker HR23B

Oxford, UK, 07 Sep 2015 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced the European Patent Office (EPO) has announced its intention to grant a patent for the use of the biomarker HR23B to predict drug sensitivity. HR23B has been shown to be predictive for HDAC and proteasome inhibitor drugs.

Nick La Thangue, CSO of Oxford Cancer Biomarkers, commented: “We are pleased to confirm OCB’s proprietary position for this clinically validated biomarker. OCB has an ever growing portfolio of effective biomarkers including HR23B which we are looking to commercialise over the next 12 to 18 months.”

About Oxford Cancer Biomarkers

Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Medical Sciences Division. The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University.

For more information, please visit www.oxfordcancerbiomarkers.com or contact Nick La Thangue, CSO, on +44 1865 784743

Oxford Cancer Biomarkers announces funding has been awarded for a pilot study of the ColoTox test

Oxford, UK, 16th January 2015 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced that the Thames Valley Cancer SCN Project has awarded funding for a pilot study to measure the clinical utility of OCB’s ColoTox test for patients undergoing adjuvant treatment for colorectal cancer. The project is a collaboration between Oxford cancer Biomarkers and the Oxford University Hospitals Trust.

The ColoTox test predicts which patients are at risk of severe side effects upon treatment with5-fluorouracil based drugs such as capecitabine so elective dose reduction can be considered prior to dosing preventing toxicity. The aims of the pilot study are to:

  • Assess the uptake of a novel genetic test that can predict potential risk of high grade toxicity prior to first exposure
  • Assess the impact of the results of the assay on the capecitabine / 5FU dosing decisions made for the first cycle of treatment
  • Assess the impact of the assay results / a priori dose reductions on the frequency of high grade / life-threatening toxicities (presently 30%)
  • Assess the impact of the above on frequency and duration of emergency admissions and other interventions.

David Kerr CMO of Oxford Cancer Biomarkers, commented: “For the first time, through the use of the ColoTox test, we should be able to reduce drug toxicity for colorectal cancer patients while creating health economic savings for the NHS. This is an important example of Oxford Cancer Biomarkers vision for the future of personalised medicine.”

About Oxford Cancer Biomarkers

Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Medical Sciences Division in Oxford University. The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University. Its major investor is Quintiles with whom it also has a strategic relationship in the biomarker space. For more information, please visit http://www.oxfordcancerbiomarkers.com or contact Nick La Thangue, CEO, on +44 1865 784743

Oxford Cancer Biomarkers announces biomarker discovery and development deal with Daiichi-Sankyo

Oxford, UK, 29th August 2014 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced an agreement with Daiichi-Sankyo for biomarker discovery, with the potential for further collaboration on validation and development of resulting biomarkers.

OCB will work with a Daiichi-Sankyo cancer drug to discover biomarkers that have the potential to predict patients that will or will not respond to the drug. Under the terms of the agreement, Daiichi-Sankyo has an option to license biomarkers from the programme.

Nick La Thangue CEO of Oxford Cancer Biomarkers, commented: “The discovery and development of biomarkers of drug response as a basis for developing companion diagnostic tests is becoming an essential component of cancer drug development, clinical trials, regulatory approval and commercialisation. With more targeted treatments being made available for defined patient populations, the need for companion diagnostics is growing. We are delighted to be working with Daiichi-Sankyo on this important program.”

Oxford Cancer Biomarkers uses its proprietary platform, CancerNav® and ToxNav to rapidly generate predictive biomarkers for cancer drugs. It has successfully proven its platform from biomarker discovery through to clinical validation.

About Oxford Cancer Biomarkers

Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Medical Sciences Division in Oxford University. The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University. Its major investor is Quintiles with whom it also has a strategic relationship in the biomarker space. For more information, please visit http://www.oxfordcancerbiomarkers.com or contact Nick La Thangue, CEO, on +44 1865 784743

About Daiichi-Sankyo

For more information please visit: http://www.daiichisankyo.com/

Oxford Cancer Biomarkers announces issued United States patent

Oxford, UK, 24 July 2014 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced that the United States patent for its biomarker platform CancerNav® has been issued. CancerNav® provides a powerful approach to discovering biomarkers that have the potential to predict responding and non-responding patients to a cancer drug. The platform is widely applicable to diverse cancer drugs and OCB has deployed it to successfully identify predictive biomarkers that can be developed as companion diagnostics for a variety of cancer drugs.

Nick La Thangue, CSO of Oxford Cancer Biomarkers, commented: “The issue of the United States patent is a major step forward in strengthening OCB’s position in biomarker discovery for personalised cancer medicine. It is an important milestone in attracting new partners to work with us.”

About Oxford Cancer Biomarkers

Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Medical Sciences Division. The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University. Its major investor is Quintiles with whom it also has a strategic relationship in the biomarker space.

For more information, please visit www.oxfordcancerbiomarkers.com or contact Nick La Thangue, CSO, on +44 1865 784743

Oxford Cancer Biomarkers announces biomarker discovery deal with AstraZeneca

Oxford, UK, 15th April 2013 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced an agreement with AstraZeneca for biomarker discovery, with the potential for further collaboration on validation and development of resulting biomarkers.

OCB will work with an undisclosed AstraZeneca cancer drug to discover biomarkers that have the potential to predict responders and non-responders to the drug. Under the agreement, AstraZeneca has been granted an option to license biomarkers from the programme.

Nick McCooke, CEO of Oxford Cancer Biomarkers, commented: “The discovery and development of biomarkers of drug response is becoming an essential component of cancer drug development and commercialisation. With more targeted treatments being made available for more defined patient populations, the need for companion diagnostics is growing. We are a young company but already making a name for ourselves in the cancer biomarkers space, and we are delighted to be working with AstraZeneca on this important program.”

Andrew Hughes, Vice President of Clinical Oncology at AstraZeneca said: “Identifying the right patients is key for the development of AstraZeneca’s targeted oncology drugs. We are excited to be working with Oxford Cancer Biomarkers to explore how their novel approaches can contribute to our biomarker strategy in the early stages of drug development.”

Oxford Cancer Biomarkers uses its proprietary platform CancerNav® to rapidly generate predictive biomarkers for cancer drugs. It has successfully proven its platform through from biomarker discovery to clinical validation.

The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University. Its major investor is Quintiles with whom it also has a strategic relationship in the biomarker space.

About Oxford Cancer Biomarkers

Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Its consultancy arm, Oxford Cancer Solutions works with healthcare providers to implement strategies for better value cancer care. Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Oxford Institute of Cancer Medicine. For more information, please visit www.oxfordcancerbiomarkers.com or contact Nick McCooke, CEO, on +44 1865 784743

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

Oxford Cancer Biomarkers appoints David Oxlade as its Chairman

Oxford, UK, 16 October 2013 Oxford Cancer Biomarkers has appointed David Oxlade as Chairman, a key growth milestone for the company which aims to benefit cancer patients through development of tests that allow medicines to be personalised.

Founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University, Oxford Cancer Biomarkers uses its proprietary platform CancerNav®, to rapidly generate predictive biomarkers for cancer drugs. The company has a strategic relationship with Quintiles in the biomarker space.

“We are delighted to welcome David Oxlade to Oxford Cancer Biomarkers, said Nick McCooke, CEO. His experience in building successful biotechnology businesses is particularly relevant as the Company expects to achieve substantial growth over the coming years”.

David is currently Chairman of TranScrip Partners LLP, base4innovation Ltd, and Kirkstall Ltd and previously a Non-Executive Director of Cobra Biologicals and Chairman of BioAnalab Ltd. Until 2005 David was CEO of Xenova Group plc, a LSE and NASDAQ listed oncology focused drug discov-ery and development company. Prior to joining Xenova Group, David was President of Syva Com-pany, the medical diagnostics’ business based in San Jose, California. Earlier he worked for ICI Pharmaceuticals, now AstraZeneca, during which time he oversaw the launch of Cellmark Diagnostics and its identity and forensic testing business ‘DNA Fingerprinting’ and for 14 years was with Boehringer Mannheim GmBH, now part of Roche, in Europe and the Far East.

He is an Honorary Fellow of Brunel University, a previous member of the Emerging Enterprise Council of EuropaBio and of the Bioscience Leadership Council until 2004. David Chaired the European Working Group of the Bioscience Innovation and Growth Team charged with setting out a 10 year agenda for developing the UK’s bioscience industry.

David commented: “I’m excited to be joining Oxford Cancer Biomarkers at this important stage of its development. The company has great potential, leveraging both its novel platform and its unique relationship with Quintiles, and I look forward to helping this to be fully realised”.

About Oxford Cancer Biomarkers

Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Its unique platform, CancerNav®, isolates biomarkers which allow drugs to be tailored to the disease. It is a spin-out of the University of Oxford and is located on the Oxford Science Park. For more information, please visit www.oxfordcancerbiomarkers.com.

About Quintiles

Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 27,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.

Oxford Cancer Biomarkers appoints Nick McCooke as its CEO

Oxford Cancer Biomarkers has appointed Nick McCooke as CEO, a key growth milestone for the company which aims to benefit cancer patients through development of tests that allow medicines to be personalised.

Founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University, Oxford Cancer Biomarkers uses its proprietary platform CancerNav™ to rapidly generate predictive biomarkers for cancer drugs.

“We are delighted to welcome Nick McCooke to Oxford Cancer Biomarkers, said Nick La Thangue. His experience in building successful biotech companies is exceptional – we all know the Solexa story for example – and his appointment is a timely and welcome development for the company”.

Nick McCooke was most recently CEO of Pronota, the Belgian protein biomarker company, which he led for six years, raising over €25M of venture capital funding. Previously, he was CEO of Solexa, the pioneer of Next Generation Sequencing (NGS), which he led through its ground-breaking technology development phase and to NASDAQ listing, raising over £20M in this period.

Nick commented: “I’m excited to be joining Oxford Cancer Biomarkers at this important stage of its development. The company has great potential, leveraging both its novel platform and its unique relationship with Quintiles, and I look forward to helping this to be fully realised”.

The company’s major investor is Quintiles with whom it also it has a strategic relationship in the biomarker space.

About Oxford Cancer Biomarkers

Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Its consultancy arm offers expertise in the development, placement, conduct and analysis of early phase oncology trials. It is a spin-out of the University of Oxford and has strong links with the Oxford Institute of Cancer Medicine. For more information, please visit www.oxfordcancerbiomarkers.com.

About Quintiles

Quintiles is the only fully integrated biopharmaceutical company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.

Quintiles Forms New Biomarker Research and Development Company

Professors David Kerr and Nick La Thangue offer oncology consulting and biomarker R&D activities spun out from the University of Oxford

OXFORD, U.K. and RESEARCH TRIANGLE PARK, N.C. – January 18, 2012 – Continuing its commitment to advancing personalized medicine by offering world-leading experts and cutting-edge tools, Quintiles today announced that it has invested in a new company formed to provide oncology consulting services and new cancer biomarkers, the key to scientific selection of the right drug for the right patient.

The company, Oxford Cancer Biomarkers, will develop biomarkers using CancerNav™, a proprietary DNA- and protein-based assay technology platform invented by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University. David Kerr, CBE, DSc, M.D, FMedSci., Professor of Cancer Medicine at the University of Oxford and a world-renowned expert in cancer clinical research and policy development, will serve as the new company’s Chief Medical Officer.

Quintiles is the largest shareholder in Oxford Cancer Biomarkers; other major shareholders are the University of Oxford, and Professors La Thangue and Kerr.

Biomarkers hold great promise to improve trial success rates by identifying patient sub-groups most likely to respond to treatment, increasing the probability of trial success and improving patient safety,” said Ben Cons, Vice President, Quintiles Corporate Development. “Quintiles’ investment in Oxford Cancer Biomarkers is further evidence of our commitment to provide biopharma and healthcare service providers with the tools, expertise and services needed to increase R&D productivity and speed, and better the lives of patients.”

Professor Kerr, who recently finished his term as President of the European Society of Medical Oncology, said: “We see this as a fantastic opportunity to pursue our vision of personalized medicine in which we aim to identify those cancer patients who are likely to benefit most from treatment. Our association with Quintiles is greatly welcomed and widens our access to some of the best cancer drug development teams on the planet.”

Professor La Thangue said: “Today’s announcement provides early and strong endorsement of our proprietary biomarker platform, CancerNav™, which can rapidly generate predictive biomarkers for cancer drugs. Quintiles is the ideal partner to leverage our clinical and biomarker expertise.”

Oxford Cancer Biomarkers, with offices in Oxford and Reading, U.K., will have a strategic relationship with Quintiles Consulting and Quintiles Global Laboratories, which have the capabilities and expertise to operationalize the consulting and biomarker R&D innovations from Oxford Cancer Biomarkers for the benefit of biopharma companies globally.

About Quintiles

Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.

About Oxford Cancer Biomarkers

Oxford Cancer Biomarkers translates groundbreaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalized for the benefit of the cancer patient. Its consultancy arm offers expertise in the development, placement, conduct and analysis of early phase oncology clinical trials. It is a spin-out of the University of Oxford and has strong links with the Oxford Institute of Cancer Medicine. For more information, please visit www.oxfordbio.com.

Contacts

Charlotte Taylor, Media Relations
Office: +44 1344 708386

Nick La Thangue, Oxford Cancer Biomarkers
Office: +44 1865 784743

Greg Connors, Investor Relations
Office: +1 919 998 2000